✦ LIBER ✦

Hepatitis E superinfection produces severe decompensation in patients with chronic liver disease

✍ Scribed by JEYAMANI RAMACHANDRAN; CE EAPEN; GAGANDEEP KANG; PRIYA ABRAHAM; DARIUS DJ HUBERT; GEORGE KURIAN; JULIE HEPHZIBAH; ASHIS MUKHOPADHYA; GEORGE M CHANDY

Book ID: 108949806
Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 82 KB
Volume: 19
Category: Article
ISSN: 0815-9319
DOI: 10.1111/j.1440-1746.2004.03188.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Hepatitis E virus superinfection in pati

Hepatitis E virus superinfection in patients with chronic liver disease

✍ Saeed S. Hamid; Muslim Atiq; Farooq Shehzad; Aneela Yasmeen; Tayyabun Nissa; Abd 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

Hepatitis E infection is an under recogn

Hepatitis E infection is an under recognized cause of acute decompensation in patients with chronic liver disease

✍ Sampath De Silva; Mohammed Osman Hassan-Ibrahim; Mark Austin; Melanie Newport; S 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 195 KB

472 Factors associated with liver decomp

472 Factors associated with liver decompensation in patients with chronic hepatitis B

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 117 KB

Hepatitis vaccination in patients with c

Hepatitis vaccination in patients with chronic liver disease

✍ G. Reiss; E. B. Keeffe 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB

Comparison of effects of hepatitis E or

Comparison of effects of hepatitis E or A viral superinfection in patients with chronic hepatitis B

✍ Xiaohong Zhang; Weimin Ke; Junqiang Xie; Zhixin Zhao; Dongying Xie; Zhiliang Gao 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 164 KB

Tenofovir disoproxil fumarate (TDF), emt

Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease

✍ Yun-Fan Liaw; I-Shyan Sheen; Chuan-Mo Lee; Ulus Salih Akarca; George V. Papatheo 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 271 KB

Data are limited on the safety and effectiveness of oral antivirals other than lamivudine and adefovir dipivoxil for treatment of chronic hepatitis B (CHB) in patients with decompensated liver disease. This Phase 2, double-blind study randomized 112 patients with CHB and decompensated liver disease